Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis

BACKGROUND: Ovarian function suppressor (OFS) plus either tamoxifen (TAM) or aromatase inhibitor (AI) could improve the survival outcome for premenopausal hormone receptor-positive (HR+) breast cancer. However, the optimal OFS-based regimen and medication duration remain uncertain. This article aims...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Mengjie, Chen, Wuzhen, Hu, Yujie, Chen, Chao, Li, Huafeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5750
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376312/
https://www.ncbi.nlm.nih.gov/pubmed/34414958
http://dx.doi.org/10.1097/MD.0000000000026949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376312/
https://www.ncbi.nlm.nih.gov/pubmed/34414958
http://dx.doi.org/10.1097/MD.0000000000026949

Ejemplares similares